Cat. No.: DIA-0231165
Product Information | |
---|---|
CAS No. | 1420071-30-2 |
Formula | C22H12BrN3O4S |
Molecular Weight | 494.32 |
SMILES | BrC1=CC=C(C=C1)N2C(=N)S\C(=C/C3=CC=C(O3)C4=CC=C5C(=O)NC(=O)C5=C4)C2=O |
Target | DR5 |
Product Description | Bioymifi, a small-molecule death receptor 5 (DR5) agonist, binds to the extracellular domain(ECD) of DR5 with a Kd of 1.2 μM but showed little binding affinity to the DR4 ECD. It induces DR5 clustering and aggregation, leading to apoptosis. |
Format & Storage | |
---|---|
Purity | > 99% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.